Innate Pharma (IPHA) Net Cash Flow (2019 - 2024)
Historic Net Cash Flow for Innate Pharma (IPHA) over the last 6 years, with Q4 2024 value amounting to -$13.8 million.
- Innate Pharma's Net Cash Flow rose 6287.93% to -$13.8 million in Q4 2024 from the same period last year, while for Jun 2025 it was -$50.9 million, marking a year-over-year increase of 2990.19%. This contributed to the annual value of -$4.0 million for FY2024, which is 7352.49% up from last year.
- Innate Pharma's Net Cash Flow amounted to -$13.8 million in Q4 2024, which was up 6287.93% from -$37.1 million recorded in Q4 2023.
- In the past 5 years, Innate Pharma's Net Cash Flow ranged from a high of -$1.4 million in Q2 2022 and a low of -$79.1 million during Q4 2020
- Moreover, its 5-year median value for Net Cash Flow was -$37.1 million (2023), whereas its average is -$39.2 million.
- Per our database at Business Quant, Innate Pharma's Net Cash Flow surged by 9632.11% in 2022 and then plummeted by 87583.27% in 2023.
- Over the past 5 years, Innate Pharma's Net Cash Flow (Quarter) stood at -$79.1 million in 2020, then increased by 14.09% to -$67.9 million in 2021, then soared by 68.48% to -$21.4 million in 2022, then crashed by 73.52% to -$37.1 million in 2023, then soared by 62.88% to -$13.8 million in 2024.
- Its Net Cash Flow stands at -$13.8 million for Q4 2024, versus -$37.1 million for Q4 2023 and -$14.1 million for Q2 2023.